Crystal S. Denlinger

Crystal S. Denlinger, MD, FACP, is Senior Vice President, Chief Scientific Officer at the National Comprehensive Cancer Network (NCCN). She joined NCCN in April 2021. In her role, she helps steer the strategic direction, oversees the NCCN Oncology Research Program (ORP), and provides input into NCCN’s clinical information program, including the NCCN Guidelines® and continuing education activities.

Prior to joining NCCN, Dr. Denlinger held several leadership positions with Fox Chase Cancer Center—an NCCN Member Institution—including Chief, Gastrointestinal Medical Oncology; Deputy Director, Early Drug Development Phase 1 Program; Director, Survivorship Program; and Associate Professor, Department of Hematology/Oncology. After joining NCCN, she will continue to see patients at Fox Chase Cancer Center in a limited, volunteer capacity.

Dr. Denlinger has been involved with NCCN for many years, including serving as chair of the NCCN Guidelines Panel for Survivorship and serving on a number of panels, including the Esophageal/Gastric Cancers Panel, the JNCCN—Journal of the National Comprehensive Cancer Network Editorial Board, and on various abstract committees and ORP RFP committees, including chairing two committees. She was named an NCCN Young Investigator Awardee in 2012 and received the NCCN Rodger Winn Award in 2018 for exemplifying leadership, drive, and commitment in service to developing clinical practice guidelines.

She graduated from a combined BS/MD program at The College of New Jersey and Rutgers New Jersey Medical School, followed by an internal medicine residency with Mount Sinai Medical Center, and a hematology/oncology fellowship at Fox Chase Cancer Center/Temple University Hospital. She has authored hundreds of clinical research articles and abstracts and received awards from organizations that include the American Society of Clinical Oncology (ASCO) Foundation and the American College of Physicians.